Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Classified Treatment Strategy for de novo metastatic breast cancer
NCT05285332Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2030
01
Overview
Open-label trial in breast cancer, sponsored by Changhai Hospital. Primary endpoint: Overall Survival at 5 years. Planned start Aug 2022; status: not yet recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05285332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285332.